Eterna Therapeutics (NASDAQ: BTX)
$0.40
(-8.2%)
-$0.04
Price as of January 16, 2025, 2:22 p.m. ET
Eterna Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Eterna Therapeutics Company Info
Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.
News & Analysis
Featured Article
Why Brooklyn ImmunoTherapeutics Crushed the Market Today
The biotech is bulking up with a new acquisition.
Eric Volkman | Jun 14, 2021
Featured Article
Why Brooklyn ImmunoTherapeutics Stock Crushed It in April
This clinical-stage biotech was one of April's brightest stars.
George Budwell | May 8, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.